Vikram D. Kodibagkar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Vikram D. Kodibagkar has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
Praveen K. Gulaka
Department of Radiology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, 75390, USA
4 shared publications- Ralph Peter Mason
Department of Radiology, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390-9058, United States
4 shared publications - Rohini Vidya Shankar
School of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom
3 shared publications - Sarah E. Stabenfeldt
School of Biological and Health Systems Engineering, Arizona State University, Tempe, AZ, USA
3 shared publications Vimala N. Bharadwaj
School of Biological and Health Systems Engineering Arizona State University Tempe Arizona 85287‐9709 USA
3 shared publications- Anna Rushin
Department of Biochemistry and Molecular Biology, College of Medicine, University of Florida, Gainesville, Florida, 32610
2 shared publications
Latest Publications
- 18 June 2026
- Published by Wiley in NMR in Biomedicine
- Vol. 39 (8) , e70337
AeroCoil: Pneumatically Controlled Dual‐Tunable RF Coil for Proton ( 1 H) and Deuterium ( 2 H)
In specific MRI applications, RF coils must operate at multiple resonance frequencies to support multinuclear imaging and spectroscopy. Designing such coils that can either resonate at or switch between multiple frequencies presents considerable technical challenges. Traditional multituned coils typically suffer from strong electromagnetic (EM) coupling due to limited physical space and the interaction between multiple resonating structures. Frequency‐switchable coils offer an alternative by adjusting circuit capacitance or inductance to tune for different nuclei, typically relying on PIN diodes or similar electronic switches. However, these designs require frequency‐sensitive bias circuitry, dedicated drivers, and long DC control lines, all of which are prone to RF interference within the MRI environment. Furthermore, PIN diodes introduce inherent RF leakage and nonlinearities that can significantly degrade image quality. This study introduces a pneumatically actuated frequency‐switchable RF coil, termed AeroCoil, that enables resonance switching without electrical biasing. The AeroCoil design utilizes air pressure to mechanically adjust capacitance, enabling transitions between the 1 H and 2 H Larmor frequencies at 9.4 T. This pneumatic mechanism eliminates the need for local electrical components near the imaging volume, thereby reducing RF noise, eliminating EM interference, and simplifying the coil's circuit architecture. The AeroCoil's performance was benchmarked against single‐tuned coils, representing optimal performance at each frequency, and a PIN diode‐based switchable coil. Bench measurements evaluated return losses and quality factors, whereas MRI experiments assessed SNR and image artifacts. The AeroCoil retained 88.2%–91.9% of the SNR compared with a single‐tuned 1 H coil, whereas the PIN diode‐based 1 H coil achieved only 68.3%–75%. At the 2 H frequency, AeroCoil performance was further emphasized, retaining 71.7%–74.6% SNR, whereas the PIN diode‐based design dropped sharply to 27.1%–28.8%.
- 18 June 2026
- Published by Wiley in NMR in Biomedicine
- Vol. 39 (8) , e70337
AeroCoil: Pneumatically Controlled Dual‐Tunable RF Coil for Proton ( 1 H) and Deuterium ( 2 H)
In specific MRI applications, RF coils must operate at multiple resonance frequencies to support multinuclear imaging and spectroscopy. Designing such coils that can either resonate at or switch between multiple frequencies presents considerable technical challenges. Traditional multituned coils typically suffer from strong electromagnetic (EM) coupling due to limited physical space and the interaction between multiple resonating structures. Frequency‐switchable coils offer an alternative by adjusting circuit capacitance or inductance to tune for different nuclei, typically relying on PIN diodes or similar electronic switches. However, these designs require frequency‐sensitive bias circuitry, dedicated drivers, and long DC control lines, all of which are prone to RF interference within the MRI environment. Furthermore, PIN diodes introduce inherent RF leakage and nonlinearities that can significantly degrade image quality. This study introduces a pneumatically actuated frequency‐switchable RF coil, termed AeroCoil, that enables resonance switching without electrical biasing. The AeroCoil design utilizes air pressure to mechanically adjust capacitance, enabling transitions between the 1 H and 2 H Larmor frequencies at 9.4 T. This pneumatic mechanism eliminates the need for local electrical components near the imaging volume, thereby reducing RF noise, eliminating EM interference, and simplifying the coil's circuit architecture. The AeroCoil's performance was benchmarked against single‐tuned coils, representing optimal performance at each frequency, and a PIN diode‐based switchable coil. Bench measurements evaluated return losses and quality factors, whereas MRI experiments assessed SNR and image artifacts. The AeroCoil retained 88.2%–91.9% of the SNR compared with a single‐tuned 1 H coil, whereas the PIN diode‐based 1 H coil achieved only 68.3%–75%. At the 2 H frequency, AeroCoil performance was further emphasized, retaining 71.7%–74.6% SNR, whereas the PIN diode‐based design dropped sharply to 27.1%–28.8%.
- Open Access
Comparison of HDO production from [2,3,4,6,6- 2 H 5 ]Glucose and [ 2 H 7 ]Glucose as a marker of Glucose metabolism
PURPOSE: Glycolytic production of HDO from the metabolism of perdeuterated glucose provides a means for metabolic imaging with 2 H MRI. The present study compared HDO production from a cost-efficient [2,3,4,6,6- 2 H 5 ]glucose with [ 2 H 7 ]glucose in vitro and in vivo . METHODS: 2 H NMR spectroscopy was performed to measure glucose consumption, lactate, and HDO production in the SFxL glioblastoma cell line. In vivo studies in healthy mice using 2 H magnetic resonance spectroscopy were performed at 11.1 T after administering a bolus of either metabolic contrast agent. In vivo metabolite levels were quantified using unlocalized and slice-selective localized spectra. RESULTS: Our in vitro results demonstrated similar glucose consumption and HDO production kinetics, although significant differences in lactate labeling were observed. The in vivo study showed comparable glucose consumption and HDO production kinetics following tail-vein bolus administration of either metabolic contrast agent, while lactate was not detected in the brain. CONCLUSION: [2,3,4,6,6- 2 H 5 ]glucose shows comparable HDO production to [ 2 H 7 ]glucose, while offering lower cost and reduced spectral complexity. These findings place [2,3,4,6,6- 2 H 5 ]glucose as an alternative to [ 2 H 7 ]glucose for HDO-based DMI studies.
Open AccessComparison of HDO production from [2,3,4,6,6- 2 H 5 ]Glucose and [ 2 H 7 ]Glucose as a marker of Glucose metabolism
PURPOSE: Glycolytic production of HDO from the metabolism of perdeuterated glucose provides a means for metabolic imaging with 2 H MRI. The present study compared HDO production from a cost-efficient [2,3,4,6,6- 2 H 5 ]glucose with [ 2 H 7 ]glucose in vitro and in vivo . METHODS: 2 H NMR spectroscopy was performed to measure glucose consumption, lactate, and HDO production in the SFxL glioblastoma cell line. In vivo studies in healthy mice using 2 H magnetic resonance spectroscopy were performed at 11.1 T after administering a bolus of either metabolic contrast agent. In vivo metabolite levels were quantified using unlocalized and slice-selective localized spectra. RESULTS: Our in vitro results demonstrated similar glucose consumption and HDO production kinetics, although significant differences in lactate labeling were observed. The in vivo study showed comparable glucose consumption and HDO production kinetics following tail-vein bolus administration of either metabolic contrast agent, while lactate was not detected in the brain. CONCLUSION: [2,3,4,6,6- 2 H 5 ]glucose shows comparable HDO production to [ 2 H 7 ]glucose, while offering lower cost and reduced spectral complexity. These findings place [2,3,4,6,6- 2 H 5 ]glucose as an alternative to [ 2 H 7 ]glucose for HDO-based DMI studies.
- Open Access
- 31 December 2025
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
PISTOL MRI allows noninvasive assessment of changes in tumor oxygenation post hypoxia targeted therapy
Tumor hypoxia has been shown to promote tumor progression, cause resistance to both radiotherapy and chemotherapy and is a marker for poor prognosis. Due to its ability to modulate the clinical outcome, hypoxia has been recognized as a tumor-specific target for development of novel hypoxia-activated/targeted bioreductive pro-drugs. In the present study, a 1H MRI based pO2 measuring technique, PISTOL (Proton Imaging of Siloxanes to map Tissue Oxygenation Levels), was used to determine the baseline oxygenation of pre-clinical models of non-small cell lung cancer (NCI-H1975) and epidermoid carcinoma (A431) and their response to hypoxia-activated pro-drug (HAP) Tirapazamine (TPZ). A431 tumors had lower baseline oxygenation than the NCI-H1975 tumors (p < 0.05). TPZ was effective in slowing the tumor growth only in NCI-H1975 tumors, even though A431 tumors were significantly less oxygenated (50 ± 14 torr for NCI-H1975 vs. 30 ± 11 torr for A431, p < 0.0001) and had similar hypoxic fractions (0.08 ± 0.09 for NCI-H1975 vs. 0.18 ± 0.19 for A431, p > 0.05) pre-treatment.TPZ resulted in a significant decrease (p < 0.05) in the oxygenation of central regions of NCI-H1975 tumor, and an increase in the edema fraction which can be attributed to its reported anti-vascular effect. In conclusion, PISTOL was able to report the changes in tumor oxygenation in both the tumor xenografts over time and in response to therapy. The baseline mean pO2 and hypoxic fraction alone were not a reliable indicator of therapeutic efficacy and the results indicate that other factors (e.g. tumor perfusion and relative expression of nitroreductases) may play an important role in determining efficacy of hypoxia-targeted treatments in conjunction with tumor oxygenation status.
- 31 December 2025
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessPISTOL MRI allows noninvasive assessment of changes in tumor oxygenation post hypoxia targeted therapy
Tumor hypoxia has been shown to promote tumor progression, cause resistance to both radiotherapy and chemotherapy and is a marker for poor prognosis. Due to its ability to modulate the clinical outcome, hypoxia has been recognized as a tumor-specific target for development of novel hypoxia-activated/targeted bioreductive pro-drugs. In the present study, a 1H MRI based pO2 measuring technique, PISTOL (Proton Imaging of Siloxanes to map Tissue Oxygenation Levels), was used to determine the baseline oxygenation of pre-clinical models of non-small cell lung cancer (NCI-H1975) and epidermoid carcinoma (A431) and their response to hypoxia-activated pro-drug (HAP) Tirapazamine (TPZ). A431 tumors had lower baseline oxygenation than the NCI-H1975 tumors (p < 0.05). TPZ was effective in slowing the tumor growth only in NCI-H1975 tumors, even though A431 tumors were significantly less oxygenated (50 ± 14 torr for NCI-H1975 vs. 30 ± 11 torr for A431, p < 0.0001) and had similar hypoxic fractions (0.08 ± 0.09 for NCI-H1975 vs. 0.18 ± 0.19 for A431, p > 0.05) pre-treatment.TPZ resulted in a significant decrease (p < 0.05) in the oxygenation of central regions of NCI-H1975 tumor, and an increase in the edema fraction which can be attributed to its reported anti-vascular effect. In conclusion, PISTOL was able to report the changes in tumor oxygenation in both the tumor xenografts over time and in response to therapy. The baseline mean pO2 and hypoxic fraction alone were not a reliable indicator of therapeutic efficacy and the results indicate that other factors (e.g. tumor perfusion and relative expression of nitroreductases) may play an important role in determining efficacy of hypoxia-targeted treatments in conjunction with tumor oxygenation status.
- Open Access
Tissue-Adhesive Endoscopic Tattoo Inks for Precise Marking and Surveillance of Gastrointestinal Lesions
Accurate marking of lesions and polyps is essential for effective management of gastrointestinal (GI) diseases, including colorectal cancer. Existing FDA-approved endoscopic carbon suspensions diffuse extensively within tissue and can extravasate intraperitoneally, compromising lesion localization, increasing fibrosis risk, and triggering inflammatory responses. These limitations reduce surgical precision and adversely affect patient outcomes. Here, we developed Tissue Adhesive Tattoos, generation 2 (TAT2) inks, composed of iron oxide nanoparticles encapsulated in bioadhesive polymers to improve spatial accuracy while maintaining high endoscopic contrast. TAT2 inks exhibit easy injectability, long-term stability, low macrophage inflammation, and strong spatial localization in ex vivo porcine intestinal tissue. Compared to clinical carbon ink, which spreads widely, TAT2 inks remained sharply localized with excellent contrast after submucosal injection in live mice and pigs. TAT2 also enabled visualization from both luminal and serosal surfaces and supported precise quadrant marking. Additionally, TAT2 inks were MR-compatible, expanding multimodality. Overall, TAT2 inks are biocompatible, non-inflammatory, precisely localized, and improve endoscopic marking for GI disease. Teaser: Engineered bioadhesive tattoo inks deliver precise, durable GI marking with minimal spread and compatibility across imaging modalities.
Open AccessTissue-Adhesive Endoscopic Tattoo Inks for Precise Marking and Surveillance of Gastrointestinal Lesions
Accurate marking of lesions and polyps is essential for effective management of gastrointestinal (GI) diseases, including colorectal cancer. Existing FDA-approved endoscopic carbon suspensions diffuse extensively within tissue and can extravasate intraperitoneally, compromising lesion localization, increasing fibrosis risk, and triggering inflammatory responses. These limitations reduce surgical precision and adversely affect patient outcomes. Here, we developed Tissue Adhesive Tattoos, generation 2 (TAT2) inks, composed of iron oxide nanoparticles encapsulated in bioadhesive polymers to improve spatial accuracy while maintaining high endoscopic contrast. TAT2 inks exhibit easy injectability, long-term stability, low macrophage inflammation, and strong spatial localization in ex vivo porcine intestinal tissue. Compared to clinical carbon ink, which spreads widely, TAT2 inks remained sharply localized with excellent contrast after submucosal injection in live mice and pigs. TAT2 also enabled visualization from both luminal and serosal surfaces and supported precise quadrant marking. Additionally, TAT2 inks were MR-compatible, expanding multimodality. Overall, TAT2 inks are biocompatible, non-inflammatory, precisely localized, and improve endoscopic marking for GI disease. Teaser: Engineered bioadhesive tattoo inks deliver precise, durable GI marking with minimal spread and compatibility across imaging modalities.
- Open Access
2 H MRI-based quantification of leucine uptake in glioblastoma multiforme
Glioblastoma (GBM) brain tumors are among the most lethal of all human cancers, with a median survival time of ∼15 months. Treatment planning requires radiologic demarcation of tumor boundaries with contrast-enhanced magnetic resonance imaging (CE MRI); however, significant tumor burden extends beyond the contrast-enhancing margins of the tumor. GBM tumors have an increased expression of amino acid (AA) transporters, including the Alanine, Serine, Cysteine Transporter 2 (ASCT2) and the L-Type Amino Acid Transporter 1 (LAT1). This upregulation has been leveraged in positron emission tomography (PET) studies to detect tumor burden beyond the contrast-enhancing margins identified by standard-of-care CE MRI. Here we leverage recent approaches in deuterium metabolic magnetic resonance with this known upregulation of AA transporters in GBM to demonstrate that 2 H MR can detect glioma based on enhanced branched- chain amino acid (BCAA) uptake. To the best of our knowledge, these data represent the first non- invasive quantification of AA concentrations in brain tumor and raises the potential to (i) detect tumor burden beyond contrast-enhancing margins and (ii) quantify AA metabolism using 2 H MR spectroscopy.
Open Access2 H MRI-based quantification of leucine uptake in glioblastoma multiforme
Glioblastoma (GBM) brain tumors are among the most lethal of all human cancers, with a median survival time of ∼15 months. Treatment planning requires radiologic demarcation of tumor boundaries with contrast-enhanced magnetic resonance imaging (CE MRI); however, significant tumor burden extends beyond the contrast-enhancing margins of the tumor. GBM tumors have an increased expression of amino acid (AA) transporters, including the Alanine, Serine, Cysteine Transporter 2 (ASCT2) and the L-Type Amino Acid Transporter 1 (LAT1). This upregulation has been leveraged in positron emission tomography (PET) studies to detect tumor burden beyond the contrast-enhancing margins identified by standard-of-care CE MRI. Here we leverage recent approaches in deuterium metabolic magnetic resonance with this known upregulation of AA transporters in GBM to demonstrate that 2 H MR can detect glioma based on enhanced branched- chain amino acid (BCAA) uptake. To the best of our knowledge, these data represent the first non- invasive quantification of AA concentrations in brain tumor and raises the potential to (i) detect tumor burden beyond contrast-enhancing margins and (ii) quantify AA metabolism using 2 H MR spectroscopy.
- Open Access
- 28 March 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (13) , eadr0568
Assessing cancer therapeutic efficacy in vivo using [ 2 H 7 ]glucose deuterium metabolic imaging
Metabolic imaging produces powerful visual assessments of organ function in vivo. Current techniques can be improved by safely increasing metabolic contrast. The gold standard, 2-[ 18 F]fluorodeoxyglucose-positron emission tomography (FDG-PET) imaging, is limited by radioactive exposure and sparse assessment of metabolism beyond glucose uptake and retention. Deuterium magnetic resonance imaging (DMRI) with [6,6- 2 H 2 ]glucose is nonradioactive, achieves tumor metabolic contrast, but can be improved by enriched contrast from deuterated water (HDO) based imaging. Here, we developed a DMRI protocol employing [ 2 H 7 ]glucose. Imaging 2 H-signal and measuring HDO production in tumor-bearing mice detected differential glucose utilization across baseline tumors, tumors treated with vehicle control or anti-glycolytic BRAFi and MEKi therapy, and contralateral healthy tissue. Control tumors generated the most 2 H-signal and HDO. To our knowledge this is the first application of DMRI with [ 2 H 7 ]glucose for tumoral treatment monitoring. This approach demonstrates HDO as a marker of tumor glucose utilization and suggests translational capability in humans due to its safety, noninvasiveness, and suitability for serial monitoring.
- 28 March 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (13) , eadr0568
Open AccessAssessing cancer therapeutic efficacy in vivo using [ 2 H 7 ]glucose deuterium metabolic imaging
Metabolic imaging produces powerful visual assessments of organ function in vivo. Current techniques can be improved by safely increasing metabolic contrast. The gold standard, 2-[ 18 F]fluorodeoxyglucose-positron emission tomography (FDG-PET) imaging, is limited by radioactive exposure and sparse assessment of metabolism beyond glucose uptake and retention. Deuterium magnetic resonance imaging (DMRI) with [6,6- 2 H 2 ]glucose is nonradioactive, achieves tumor metabolic contrast, but can be improved by enriched contrast from deuterated water (HDO) based imaging. Here, we developed a DMRI protocol employing [ 2 H 7 ]glucose. Imaging 2 H-signal and measuring HDO production in tumor-bearing mice detected differential glucose utilization across baseline tumors, tumors treated with vehicle control or anti-glycolytic BRAFi and MEKi therapy, and contralateral healthy tissue. Control tumors generated the most 2 H-signal and HDO. To our knowledge this is the first application of DMRI with [ 2 H 7 ]glucose for tumoral treatment monitoring. This approach demonstrates HDO as a marker of tumor glucose utilization and suggests translational capability in humans due to its safety, noninvasiveness, and suitability for serial monitoring.
- 9 September 2021
- Published by Wiley in Journal of Magnetic Resonance Imaging
- Vol. 55 (4) , 1161-1168
GdDO3NI Enhanced Magnetic Resonance Imaging Allows Imaging of Hypoxia After Brain Injury
Background: Brain tissue hypoxia is a common consequence of traumatic brain injury (TBI) due to the rupture of blood vessels during impact and it correlates with poor outcome. The current magnetic resonance imaging (MRI) techniques are unable to provide a direct map of tissue hypoxia.Purpose: To investigate whether GdDO3NI, a nitroimidazole‐based T1 MRI contrast agent allows imaging hypoxia in the injured brain after experimental TBI.Study Type: Prospective.Animal Model: TBI‐induced mice (controlled cortical impact model) were intravenously injected with either conventional T1 agent (gadoteridol) or GdDO3NI at 0.3 mmol/kg dose (n = 5 for each cohort) along with pimonidazole (60 mg/kg) at 1 hour postinjury and imaged for 3 hours following which they were euthanized.Field Strength/Sequence: 7 T/T2‐weighted spin echo and T1‐weighted gradient echo.Assessment: Injured animals were imaged with T2‐weighted spin‐echo sequence to estimate the extent of the injury. The mice were then imaged precontrast and postcontrast using a T1‐weighted gradient‐echo sequence for 3 hours postcontrast. Regions of interests were drawn on the brain injury region, the contralateral brain as well as on the cheek muscle region for comparison of contrast kinetics. Brains were harvested immediately post‐imaging for immunohistochemical analysis.Statistical Tests: One‐way analysis of variance and two‐sample t‐tests were performed with a P < 0.05 was considered statistically significant.Results: GdDO3NI retention in the injury region at 2.5–3 hours post‐injection was significantly higher compared to gadoteridol (mean retention fraction 63.95% ± 27.43% vs. 20.68% ± 7.43% for gadoteridol at 3 hours) while it rapidly cleared out of the muscle region. Pimonidazole staining confirmed the presence of hypoxia in both gadoteridol and GdDO3NI cohorts, and the later cohort showed good agreement with MRI contrast enhancement.Data Conclusion: GdDO3NI was successfully shown to visualize hypoxia in the brain post‐TBI using T1‐weighted MRI at 2.5–3 hours postcontrast.Evidence Level: 1Technical Efficacy: Stage 1
- 9 September 2021
- Published by Wiley in Journal of Magnetic Resonance Imaging
- Vol. 55 (4) , 1161-1168
GdDO3NI Enhanced Magnetic Resonance Imaging Allows Imaging of Hypoxia After Brain Injury
Background: Brain tissue hypoxia is a common consequence of traumatic brain injury (TBI) due to the rupture of blood vessels during impact and it correlates with poor outcome. The current magnetic resonance imaging (MRI) techniques are unable to provide a direct map of tissue hypoxia.Purpose: To investigate whether GdDO3NI, a nitroimidazole‐based T1 MRI contrast agent allows imaging hypoxia in the injured brain after experimental TBI.Study Type: Prospective.Animal Model: TBI‐induced mice (controlled cortical impact model) were intravenously injected with either conventional T1 agent (gadoteridol) or GdDO3NI at 0.3 mmol/kg dose (n = 5 for each cohort) along with pimonidazole (60 mg/kg) at 1 hour postinjury and imaged for 3 hours following which they were euthanized.Field Strength/Sequence: 7 T/T2‐weighted spin echo and T1‐weighted gradient echo.Assessment: Injured animals were imaged with T2‐weighted spin‐echo sequence to estimate the extent of the injury. The mice were then imaged precontrast and postcontrast using a T1‐weighted gradient‐echo sequence for 3 hours postcontrast. Regions of interests were drawn on the brain injury region, the contralateral brain as well as on the cheek muscle region for comparison of contrast kinetics. Brains were harvested immediately post‐imaging for immunohistochemical analysis.Statistical Tests: One‐way analysis of variance and two‐sample t‐tests were performed with a P < 0.05 was considered statistically significant.Results: GdDO3NI retention in the injury region at 2.5–3 hours post‐injection was significantly higher compared to gadoteridol (mean retention fraction 63.95% ± 27.43% vs. 20.68% ± 7.43% for gadoteridol at 3 hours) while it rapidly cleared out of the muscle region. Pimonidazole staining confirmed the presence of hypoxia in both gadoteridol and GdDO3NI cohorts, and the later cohort showed good agreement with MRI contrast enhancement.Data Conclusion: GdDO3NI was successfully shown to visualize hypoxia in the brain post‐TBI using T1‐weighted MRI at 2.5–3 hours postcontrast.Evidence Level: 1Technical Efficacy: Stage 1
- Open Access
GdDO3NI allows imaging of hypoxia after brain injury
Purpose: In this study, we use the hypoxia targeting agent (GdDO3NI, a nitroimidazole-based T 1 MRI contrast agent) for imaging hypoxia in the injured brain after experimental traumatic brain injury (TBI) using magnetic resonance imaging (MRI), and validate the results with immunohistochemistry (IHC) using pimonidazole. Methods: TBI induced mice (controlled cortical impact model) were imaged at 7T using a T 2 weighted fast spin-echo sequence to estimate the extent of the injury. The mice were then were intravenously injected with either conventional T 1 agent (gadoteridol) or GdDO3NI at 0.3 mmol/kg dose (n=5 for each cohort) along with pimonidazole (60 mg/kg). Mice were imaged pre- and post-contrast using a T 1 -weighted spin-echo sequence for three hours. Regions of interests were drawn on the brain injury region, the contralateral brain as well as on the cheek muscle region for comparison of contrast kinetics. Brains were harvested immediately post imaging for immunohistochemical analysis. Results: GdDO3NI is retained in the injury region for up to 3 hours post-injection (p< 0.05 compared to gadoteridol) while it rapidly clears out of the muscle region. On the other hand, conventional MRI contrast agent gadoteridol clears out of both the injury region and muscle rapidly, although with a relatively more delayed wash out in the injury region. Minimal contrast enhancement was seen for both agents in the contralateral hemisphere. Pimonidazole staining confirms the presence of hypoxia in both gadoteridol and GdDO3NI cohorts, and the later cohort shows good agreement with MRI contrast enhancement. Conclusion: GdDO3NI was successfully shown to visualize hypoxia in the brain post-TBI using T1-wt MRI.
Open AccessGdDO3NI allows imaging of hypoxia after brain injury
Purpose: In this study, we use the hypoxia targeting agent (GdDO3NI, a nitroimidazole-based T 1 MRI contrast agent) for imaging hypoxia in the injured brain after experimental traumatic brain injury (TBI) using magnetic resonance imaging (MRI), and validate the results with immunohistochemistry (IHC) using pimonidazole. Methods: TBI induced mice (controlled cortical impact model) were imaged at 7T using a T 2 weighted fast spin-echo sequence to estimate the extent of the injury. The mice were then were intravenously injected with either conventional T 1 agent (gadoteridol) or GdDO3NI at 0.3 mmol/kg dose (n=5 for each cohort) along with pimonidazole (60 mg/kg). Mice were imaged pre- and post-contrast using a T 1 -weighted spin-echo sequence for three hours. Regions of interests were drawn on the brain injury region, the contralateral brain as well as on the cheek muscle region for comparison of contrast kinetics. Brains were harvested immediately post imaging for immunohistochemical analysis. Results: GdDO3NI is retained in the injury region for up to 3 hours post-injection (p< 0.05 compared to gadoteridol) while it rapidly clears out of the muscle region. On the other hand, conventional MRI contrast agent gadoteridol clears out of both the injury region and muscle rapidly, although with a relatively more delayed wash out in the injury region. Minimal contrast enhancement was seen for both agents in the contralateral hemisphere. Pimonidazole staining confirms the presence of hypoxia in both gadoteridol and GdDO3NI cohorts, and the later cohort shows good agreement with MRI contrast enhancement. Conclusion: GdDO3NI was successfully shown to visualize hypoxia in the brain post-TBI using T1-wt MRI.
- Open Access
- 29 January 2020
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-10
More bullets for PISTOL: linear and cyclic siloxane reporter probes for quantitative 1H MR oximetry
Tissue oximetry can assist in diagnosis and prognosis of many diseases and enable personalized therapy. Previously, we reported the ability of hexamethyldisiloxane (HMDSO) for accurate measurements of tissue oxygen tension (pO2) using Proton Imaging of Siloxanes to map Tissue Oxygenation Levels (PISTOL) magnetic resonance imaging. Here we report the feasibility of several commercially available linear and cyclic siloxanes (molecular weight 162–410 g/mol) as PISTOL-based oxygen reporters by characterizing their calibration constants. Further, field and temperature dependence of pO2 calibration curves of HMDSO, octamethyltrisiloxane (OMTSO) and polydimethylsiloxane (PDMSO) were also studied. The spin-lattice relaxation rate R1 of all siloxanes studied here exhibited a linear relationship with oxygenation (R1 = A′ + B′*pO2) at all temperatures and field strengths evaluated here. The sensitivity index η( = B′/A′) decreased with increasing molecular weight with values ranged from 4.7 × 10−3–11.6 × 10−3 torr−1 at 4.7 T. No substantial change in the anoxic relaxation rate and a slight decrease in pO2 sensitivity was observed at higher magnetic fields of 7 T and 9.4 T for HMDSO and OMTSO. Temperature dependence of calibration curves for HMDSO, OMTSO and PDMSO was small and simulated errors in pO2 measurement were 1–2 torr/°C. In summary, we have demonstrated the feasibility of various linear and cyclic siloxanes as pO2-reporters for PISTOL-based oximetry.
- 29 January 2020
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-10
Open AccessMore bullets for PISTOL: linear and cyclic siloxane reporter probes for quantitative 1H MR oximetry
Tissue oximetry can assist in diagnosis and prognosis of many diseases and enable personalized therapy. Previously, we reported the ability of hexamethyldisiloxane (HMDSO) for accurate measurements of tissue oxygen tension (pO2) using Proton Imaging of Siloxanes to map Tissue Oxygenation Levels (PISTOL) magnetic resonance imaging. Here we report the feasibility of several commercially available linear and cyclic siloxanes (molecular weight 162–410 g/mol) as PISTOL-based oxygen reporters by characterizing their calibration constants. Further, field and temperature dependence of pO2 calibration curves of HMDSO, octamethyltrisiloxane (OMTSO) and polydimethylsiloxane (PDMSO) were also studied. The spin-lattice relaxation rate R1 of all siloxanes studied here exhibited a linear relationship with oxygenation (R1 = A′ + B′*pO2) at all temperatures and field strengths evaluated here. The sensitivity index η( = B′/A′) decreased with increasing molecular weight with values ranged from 4.7 × 10−3–11.6 × 10−3 torr−1 at 4.7 T. No substantial change in the anoxic relaxation rate and a slight decrease in pO2 sensitivity was observed at higher magnetic fields of 7 T and 9.4 T for HMDSO and OMTSO. Temperature dependence of calibration curves for HMDSO, OMTSO and PDMSO was small and simulated errors in pO2 measurement were 1–2 torr/°C. In summary, we have demonstrated the feasibility of various linear and cyclic siloxanes as pO2-reporters for PISTOL-based oximetry.
- Open Access
Sex-dependent macromolecule and nanoparticle delivery in experimental brain injury
Development of effective therapeutics for brain disorders is challenging, in particular, the blood-brain barrier (BBB) severely limits access of the therapeutics into the brain parenchyma. Traumatic brain injury (TBI) may lead to transient BBB permeability that affords a unique opportunity for therapeutic delivery via intravenous administration ranging from macromolecules to nanoparticles (NP) for developing precision therapeutics. In this regard, we address critical gaps in understanding the range/size of therapeutics, delivery window(s), and moreover the potential impact of biological factors for optimal delivery parameters. Here we show, for the first time, to the best of our knowledge, that 24 h post-focal TBI female mice exhibit a heightened macromolecular tracer and NP accumulation compared to male mice, indicating sex-dependent differences in BBB permeability. Furthermore, we report for the first time the potential to deliver NP-based therapeutics within 3 d after focal injury in both female and male mice. The delineation of injury-induced BBB permeability with respect to sex and temporal profile is essential to more accurately tailor time-dependent precision and personalized nanotherapeutics.
Open AccessSex-dependent macromolecule and nanoparticle delivery in experimental brain injury
Development of effective therapeutics for brain disorders is challenging, in particular, the blood-brain barrier (BBB) severely limits access of the therapeutics into the brain parenchyma. Traumatic brain injury (TBI) may lead to transient BBB permeability that affords a unique opportunity for therapeutic delivery via intravenous administration ranging from macromolecules to nanoparticles (NP) for developing precision therapeutics. In this regard, we address critical gaps in understanding the range/size of therapeutics, delivery window(s), and moreover the potential impact of biological factors for optimal delivery parameters. Here we show, for the first time, to the best of our knowledge, that 24 h post-focal TBI female mice exhibit a heightened macromolecular tracer and NP accumulation compared to male mice, indicating sex-dependent differences in BBB permeability. Furthermore, we report for the first time the potential to deliver NP-based therapeutics within 3 d after focal injury in both female and male mice. The delineation of injury-induced BBB permeability with respect to sex and temporal profile is essential to more accurately tailor time-dependent precision and personalized nanotherapeutics.